Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Clinical trial NCT04348747 · RECRUITING

Trial details

NCT number: NCT04348747
Sponsor: Roswell Park Cancer Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Malignant Neoplasm in the Brain Metastatic Triple-Negative Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8

Start date: 2022-12-19
Primary completion: 2028-05-15
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.